Molidustat

Molidustat

Molidustat

Chemical compound

Molidustat is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease.[2][3] Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.[4]

Quick Facts Clinical data, Trade names ...

Veterinary use

Molidustat is indicated for the control of nonregenerative anemia associated with chronic kidney disease in cats.[1][5] The US Food and Drug Administration (FDA) conditionally approved it in May 2023.[5]

The reasonable expectation of effectiveness of Molidustat was evaluated in a study conducted in two phases.[5] The first phase involved a multi-center, double-masked, randomized, placebo-controlled field effectiveness and safety study.[5] The second phase was an unmasked, optional continuation of the field study.[5] The study enrolled 23 cats from 4 to 17 years of age from various breeds or breed mixes diagnosed with nonregenerative anemia associated with CKD.[5] The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc.[5]

References

  1. [1]
    "Archived copy". Archived from the original on 2023-05-02. Retrieved 2023-05-02.{{cite web}}: CS1 maint: archived copy as title (link)
  2. [2]
    Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U (2014). "Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects". PLOS ONE. 9 (11): e111838. Bibcode:2014PLoSO...9k1838F. doi:10.1371/journal.pone.0111838. PMC 4230943. PMID 25392999.
  3. [3]
    Gupta N, Wish JB (June 2017). "Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD". American Journal of Kidney Diseases. 69 (6): 815–826. doi:10.1053/j.ajkd.2016.12.011. PMID 28242135.
  4. [4]
    Dib J, Mongongu C, Buisson C, Molina A, Schänzer W, Thuss U, et al. (January 2017). "Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls". Drug Testing and Analysis. 9 (1): 61–67. doi:10.1002/dta.2011. PMID 27346747.
  5. [5]
    "FDA Conditionally Approves First Drug for Anemia in Cats with Chronic Kidney Disease". U.S. Food and Drug Administration (Press release). 1 May 2023. Archived from the original on 1 May 2023. Retrieved 1 May 2023. Public Domain This article incorporates text from this source, which is in the public domain.


Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Molidustat, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.